SCHEMBL13658764

SCHEMBL13658764

CCC1OC(OC)C(OC(C)=O)C(C)C1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.39
▸ F10 P00742 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ LGALS8 O00214 2/20 0.35
▸ MMP9 P14780 1/20 0.34
▸ MMP12 P39900 1/20 0.34
▸ NR3C1 P04150 1/20 0.34
▸ FYN P06241 1/20 0.34
▸ ADRA2A P08913 1/20 0.34
▸ ADORA3 P0DMS8 1/20 0.34
▸ ADRA2B P18089 1/20 0.34
▸ DRD4 P21917 1/20 0.34
▸ DRD3 P35462 1/20 0.34
▸ CA2 P00918 3/20 0.33
▸ CA12 O43570 2/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA9 Q16790 2/20 0.33
▸ OGA O60502 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20109868 0.90 CYP2D6 (0.40) BCHEF10CYP2D6THRBHSD17B10
SCHEMBL12021728 0.90 CYP2D6 (0.40) BCHEF10CYP2D6THRBHSD17B10
SCHEMBL13553167 0.90 OGA (0.40) BCHECYP2D6THRBHSD17B10NR3C1
SCHEMBL10028972 0.90 OGA (0.40) BCHECYP2D6THRBHSD17B10NR3C1
SCHEMBL27108843 0.90 OGA (0.40) BCHECYP2D6THRBHSD17B10NR3C1
SCHEMBL12378498 0.90 OGA (0.40) BCHECYP2D6THRBHSD17B10NR3C1
SCHEMBL15982003 0.90 OGA (0.40) BCHECYP2D6THRBHSD17B10NR3C1
SCHEMBL12308552 0.90 OGA (0.40) BCHECYP2D6THRBHSD17B10NR3C1
SCHEMBL14478874 0.90 OGA (0.40) BCHECYP2D6THRBHSD17B10NR3C1
SCHEMBL13658766 0.88 LGALS8 (0.40) BCHEF10CYP2D6THRBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2024-06-27 — — US disclosed
US-11718596-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-08-08 — — US disclosed
US-10005745-B2 Amyloid targeting agents and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-06-26 — — US disclosed
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME Amydis, Inc. 2016-11-10 — — US disclosed
US-20090264639-A1 Polysaccharide derivative and separating agent for optical isomer containing the same NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2009-10-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11718596-B2 Amyloid targeting agents and methods of using the same APP, CRYAA, APBA1 BCHE 66/4885F10 1929/4885CYP2D6 4354/4885
US-20240208916-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, CRYAA, APBA1 BCHE 66/4885F10 1929/4885CYP2D6 4354/4885
US-20160326126-A1 AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME APP, APBA1, CRYAA BCHE 77/4885F10 1985/4885CYP2D6 4377/4885
US-20090264639-A1 Polysaccharide derivative and separating agent for optical isomer containing the same FUT5, FUT6, DDOST BCHE 1709/4885F10 1722/4885CYP2D6 4004/4885
US-10005745-B2 Amyloid targeting agents and methods of using the same APP, APBA1, CRYAA BCHE 77/4885F10 1985/4885CYP2D6 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback